Intratumoral T3011 Trial
Phase 1/2
30
about 6.3 years
18+
6 sites in AZ, MA, PA +2
What this study is about
This trial is testing a treatment called T3011 given directly into the tumor, alone or with pembrolizumab (an intravenous medication), in people with advanced solid tumors. The goal is to see if this treatment is safe and has some effect on the cancer.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive T3011
- 2.Take T3011 + pembrolizumab
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
pembrolizumab (Immune checkpoint inhibitor; blocks PD-1 to boost T-cell attack on cancer)
infusion
Primary: Characterize the safety and tolerability of T3011 in combination with pembrolizumab, Characterize the safety and tolerability of T3011 in combination with pembrolizumab in participants who progress on T3011 alone, Safety and tolerability of T3011 dose(s) selected from Phase 1 in disease specific cohorts, Safety and tolerability of escalating doses T3011
Secondary: Disease control rate (DCR), Duration of response (DOR), Overall Survival (OS), Overall response rate (ORR), Presence of neutralizing antibodies of anti-PD-1 antibody for antidrug antibodies (ADAs) development, Progression-free survival (PFS)
Oncology